U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07158398) titled 'Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate' on Aug. 28.
Brief Summary: The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
...